Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
NCT06882096
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues. Who can join?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Adults
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Metro International Biotech, LLC
- Last updated on ClinicalTrials.gov
- May 6, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.